Jupiter Neurosciences, Inc.

NasdaqCM: JUNS · Healthcare

Positivity Index

#6,549 / 6,774

Global

#3,795 / 4,000

United States

Positivity Score

-24,648

Rank→

PosiRed: 2 active red flags (highest severity 6/10) · PosiYellow: 1 yellow flag (4/10 points) View flag history →

PosiRed · red flag

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 28 Aug 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

More details →

PosiRed · red flag

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 27 Feb 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

More details →

PosiYellow · yellow flag (stress signal)

Annual report filed late (NT 10-K)

The company filed Form NT 10-K with the SEC on 01 Apr 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.

More details →

Jupiter Neurosciences, Inc. — Overview & Financial Snapshot

Jupiter Neurosciences, Inc. (NasdaqCM: JUNS) is a Healthcare company, ranked #6,549 of 6,774 companies globally and #3,795 of 4,000 in United States on PositoAI, with a Positivity Score of -24,648. Its market capitalisation is ₹32.11 Cr ($3.40M), P/E ratio is -0.1 and P/B ratio is -9.30. It currently has 2 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 4/10 points) on record.

For financial statements, ratio trends and score history, Go Deep →

What does Jupiter Neurosciences, Inc. do?

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional…

What is Jupiter Neurosciences, Inc.'s P/E and P/B ratio?

Jupiter Neurosciences, Inc. has a P/E ratio of -0.1 and a P/B ratio of -9.30.

What is Jupiter Neurosciences, Inc.'s debt-to-equity ratio?

Jupiter Neurosciences, Inc. has a debt-to-equity ratio of -2.90.

How much does Jupiter Neurosciences, Inc. owe compared with what it owns?

Jupiter Neurosciences, Inc. owes $1.10 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.

What is Jupiter Neurosciences, Inc.'s Positivity rank?

Jupiter Neurosciences, Inc. is ranked #6,549 of 6,774 companies globally and #3,795 of 4,000 in United States on PositoAI, with a Positivity Score of -24,648.

Does Jupiter Neurosciences, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

Yes. Jupiter Neurosciences, Inc. has 2 active red flags (PosiRed) on record: Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 28 Aug 2026); Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 27 Feb 2026). It also has 1 yellow flag (PosiYellow stress signals, 4/10 points): Annual report filed late (NT 10-K).

Where can I read the latest news about Jupiter Neurosciences, Inc.?

Recent headlines about Jupiter Neurosciences, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Jupiter Neurosciences, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Jupiter Neurosciences, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.